[go: up one dir, main page]

PT2635307T - Composições farmacêuticas - Google Patents

Composições farmacêuticas

Info

Publication number
PT2635307T
PT2635307T PT118386648T PT11838664T PT2635307T PT 2635307 T PT2635307 T PT 2635307T PT 118386648 T PT118386648 T PT 118386648T PT 11838664 T PT11838664 T PT 11838664T PT 2635307 T PT2635307 T PT 2635307T
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PT118386648T
Other languages
English (en)
Original Assignee
Melinta Subsidiary Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Subsidiary Corp filed Critical Melinta Subsidiary Corp
Publication of PT2635307T publication Critical patent/PT2635307T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/22Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT118386648T 2010-11-01 2011-11-01 Composições farmacêuticas PT2635307T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40883010P 2010-11-01 2010-11-01

Publications (1)

Publication Number Publication Date
PT2635307T true PT2635307T (pt) 2020-11-03

Family

ID=46025057

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118386648T PT2635307T (pt) 2010-11-01 2011-11-01 Composições farmacêuticas

Country Status (20)

Country Link
US (1) US9409896B2 (pt)
EP (1) EP2635307B1 (pt)
JP (1) JP5902188B2 (pt)
KR (1) KR20140022773A (pt)
CN (1) CN103379917B (pt)
AU (1) AU2011323594C1 (pt)
BR (1) BR112013010714A2 (pt)
CA (1) CA2816077C (pt)
EA (1) EA028054B1 (pt)
ES (1) ES2824898T3 (pt)
HU (1) HUE051133T2 (pt)
IL (1) IL225952A0 (pt)
MX (1) MX359366B (pt)
NZ (1) NZ609964A (pt)
PH (1) PH12013500882A1 (pt)
PT (1) PT2635307T (pt)
SG (2) SG190117A1 (pt)
UA (1) UA114469C2 (pt)
WO (1) WO2012061360A2 (pt)
ZA (1) ZA201303177B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2504353B2 (en) 2009-11-23 2023-09-13 Cubist Pharmaceuticals LLC Lipopeptide compositions and related methods
PT2642996T (pt) 2010-11-24 2020-12-30 Melinta Subsidiary Corp Composições farmacêuticas
WO2013182070A1 (zh) * 2012-06-08 2013-12-12 四川贝力克生物技术有限责任公司 一种用于预防或治疗分支杆菌疾病的药物
KR102446386B1 (ko) 2014-01-10 2022-09-22 아납티스바이오, 아이엔씨. 인터루킨-33 (il-33)에 대한 항체
EP4058020A4 (en) * 2019-12-26 2023-04-12 Santa Farma Ilaç Sanayi A.S. SOLID ORAL PHARMACEUTICAL GEMIFLOXACIN MESYLATE COMPOSITION WITH IMPROVED RELEASE PROFILE AND MECHANISM OF DISINTEGRATION

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ293586B6 (cs) 1996-05-24 2004-06-16 Schering Corporation Farmaceutický prostředek obsahující protihoubové činidlo
CN1207895A (zh) * 1997-08-12 1999-02-17 陕西省西安制药厂 一种克拉霉素胶囊
DK0996429T3 (da) * 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
KR19990080453A (ko) 1998-04-17 1999-11-05 성재갑 비가역성 hiv 프로테아제 억제제를 함유하는 약제학적 조성물
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
US20020119196A1 (en) 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
AU2002325192B2 (en) * 2001-07-06 2008-05-22 Veloxis Pharmaceuticals, Inc. Controlled agglomeration
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
WO2005070904A2 (en) * 2003-06-03 2005-08-04 Rib-X Pharmaceutical, Inc. Sulfonamide compounds and methods of making and using the same
EP1656370B1 (en) 2003-06-03 2012-08-15 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
US7658944B2 (en) * 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
EP2974718A1 (en) 2005-04-29 2016-01-20 Cubist Pharmaceuticals, Inc. Therapeutic compositions
JP5534497B2 (ja) * 2005-06-08 2014-07-02 メリンタ セラピューティクス,インコーポレイテッド トリアゾール類の合成方法
AU2007223560A1 (en) * 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
TW200800179A (en) * 2006-03-06 2008-01-01 Wyeth Corp Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
EP2004150A1 (en) * 2006-03-27 2008-12-24 Panacea Biotec Ltd. Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer.
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
WO2010046933A2 (en) * 2008-10-22 2010-04-29 Rubicon Research Private Limited Pharmaceutical compositions of taste-masked linezolid

Also Published As

Publication number Publication date
SG10201508982TA (en) 2015-12-30
ES2824898T3 (es) 2021-05-13
IL225952A0 (en) 2013-07-31
HUE051133T2 (hu) 2021-03-01
US9409896B2 (en) 2016-08-09
MX359366B (es) 2018-09-26
SG190117A1 (en) 2013-06-28
CN103379917B (zh) 2016-10-12
MX2013004711A (es) 2013-08-29
AU2011323594A1 (en) 2013-05-23
PH12013500882A1 (en) 2020-10-19
US20140094463A1 (en) 2014-04-03
EP2635307A4 (en) 2014-11-05
KR20140022773A (ko) 2014-02-25
ZA201303177B (en) 2018-12-19
AU2011323594C1 (en) 2017-06-01
UA114469C2 (uk) 2017-06-26
WO2012061360A3 (en) 2012-07-12
JP2013542226A (ja) 2013-11-21
WO2012061360A2 (en) 2012-05-10
CA2816077A1 (en) 2012-05-10
JP5902188B2 (ja) 2016-04-13
AU2011323594B2 (en) 2016-12-22
CA2816077C (en) 2021-08-10
EA201390646A1 (ru) 2014-01-30
EP2635307A2 (en) 2013-09-11
CN103379917A (zh) 2013-10-30
EA028054B1 (ru) 2017-10-31
NZ609964A (en) 2015-08-28
BR112013010714A2 (pt) 2024-01-16
EP2635307B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
HK1246170A1 (zh) 藥物組合物
ZA201300458B (en) C-met-modulator pharmaceutical compositions
IL223535A (en) Solid medicinal compositions
ZA201301766B (en) Pharmaceutical compositions
PL2619182T3 (pl) Kompozycja farmaceutyczna
IL225457A0 (en) Pharmaceutical composition
ZA201300718B (en) Pharmaceutical compositions
ZA201207670B (en) Pharmaceutical compositions
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
ZA201303223B (en) Pharmaceutical compositions
ZA201303177B (en) Pharmaceutical compositions
IL226554A (en) Medicinal preparations containing alisporiovir
IL221501A (en) Medicinal product containing miramistine
GB201001911D0 (en) Pharmaceutical composition
EP2560678A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA201303732B (en) Pharmaceutical compositions
GB201008590D0 (en) Pharmaceutical compositions
GB201005403D0 (en) Novel pharmaceutical compositions
GB201019775D0 (en) Pharmaceutical composition